Lv Ye, Zhang Huiqiang, Zhao Yanjiao, Zhang Haixia, Wang Tao
Department of Oncology, General Hospital of Ningxia Medical University, Yinchuan, China.
Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Transl Breast Cancer Res. 2024 Jan 11;5:8. doi: 10.21037/tbcr-23-24. eCollection 2024.
The current study shows that the incidence rate of triple-negative breast cancer accounts for 10-17% of invasive ductal carcinoma of the breast. There is no specific treatment target, the age of onset is relatively small, and the recurrence rate is relatively fast. The prognosis of breast cancer in different subtypes is the most unsatisfactory, with a 5-year survival rate of less than 15%. We report a typical case of metastatic advanced triple-negative breast cancer who responded well to apatinib mesylate after chemotherapy failure and achieved significant progression-free survival, which is relatively rare in triple-negative breast cancer with limited treatment means.
A 55-year-old female was surgically diagnosed as triple-negative breast cancer on April 17, 2015. After surgery, she had lung metastasis after standard adjuvant chemotherapy and radiotherapy. After receiving the NX regimen (vinorelbine, capecitabine) for 8 cycles, she progressed. Because the patient refused later, she was adjusted to apatinib mesylate, and serious adverse reactions occurred during the treatment process. By adjusting the drug dose, and low-dose apatinib treatment, the lung lesions were close to complete response (CR), reaching a progression-free survival period of 45 months.
Low-dose apatinib may be a promising anti-tumor drug for triple-negative breast cancer patients, which needs more samples to verify. This case may provide a reference for the treatment selection of triple-negative metastatic breast cancer in the future.
当前研究表明，三阴性乳腺癌的发病率占乳腺浸润性导管癌的10%-17%。其没有特定的治疗靶点，发病年龄相对较小，复发率相对较快。乳腺癌不同亚型中，三阴性乳腺癌的预后最不理想，5年生存率不足15%。我们报告1例转移性晚期三阴性乳腺癌的典型病例，该病例在化疗失败后对甲磺酸阿帕替尼反应良好，实现了显著的无进展生存期，这在治疗手段有限的三阴性乳腺癌中较为罕见。
一名55岁女性于2015年4月17日经手术确诊为三阴性乳腺癌。术后，她在接受标准辅助化疗和放疗后出现肺转移。接受8周期NX方案（长春瑞滨、卡培他滨）治疗后病情进展。因患者随后拒绝进一步治疗，调整为甲磺酸阿帕替尼治疗，治疗过程中出现严重不良反应。通过调整药物剂量，采用低剂量甲磺酸阿帕替尼治疗，肺部病灶接近完全缓解（CR），无进展生存期达45个月。
低剂量甲磺酸阿帕替尼可能是一种有前景的三阴性乳腺癌抗肿瘤药物，这需要更多样本进行验证。该病例可为未来三阴性转移性乳腺癌的治疗选择提供参考。
